Insider Selling: BioLife Solutions Inc (NASDAQ:BLFS) CRO Sells 2,500 Shares of Stock

BioLife Solutions Inc (NASDAQ:BLFS) CRO James Mathers sold 2,500 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $15.65, for a total transaction of $39,125.00. Following the transaction, the executive now directly owns 19,884 shares of the company’s stock, valued at $311,184.60. The sale was disclosed in a document filed with the SEC, which is available through this link.

James Mathers also recently made the following trade(s):

  • On Thursday, December 12th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $15.00, for a total transaction of $37,500.00.
  • On Wednesday, November 27th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $16.27, for a total transaction of $40,675.00.
  • On Friday, November 29th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $16.33, for a total transaction of $40,825.00.
  • On Tuesday, November 12th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.69, for a total transaction of $41,725.00.
  • On Thursday, October 31st, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.89, for a total transaction of $42,225.00.
  • On Tuesday, October 29th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.31, for a total transaction of $43,275.00.
  • On Tuesday, October 15th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.06, for a total transaction of $40,150.00.
  • On Thursday, October 17th, James Mathers sold 2,693 shares of BioLife Solutions stock. The stock was sold at an average price of $16.42, for a total transaction of $44,219.06.
  • On Wednesday, October 2nd, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $15.78, for a total transaction of $39,450.00.
  • On Wednesday, September 18th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $20.95, for a total transaction of $52,375.00.

BioLife Solutions stock opened at $15.67 on Friday. The company has a current ratio of 6.49, a quick ratio of 5.33 and a debt-to-equity ratio of 0.01. BioLife Solutions Inc has a 1 year low of $9.15 and a 1 year high of $22.44. The company has a market cap of $308.62 million, a PE ratio of 111.93, a PEG ratio of 18.86 and a beta of 1.32. The company’s 50-day moving average is $16.43 and its two-hundred day moving average is $17.54.

Several large investors have recently made changes to their positions in the stock. FMR LLC acquired a new stake in BioLife Solutions during the 1st quarter valued at $2,684,000. Alpine Woods Capital Investors LLC acquired a new stake in shares of BioLife Solutions in the second quarter worth $170,000. JPMorgan Chase & Co. acquired a new stake in shares of BioLife Solutions in the second quarter worth $30,000. Menta Capital LLC acquired a new stake in shares of BioLife Solutions in the second quarter worth $202,000. Finally, Allianz Asset Management GmbH lifted its stake in shares of BioLife Solutions by 7.4% in the second quarter. Allianz Asset Management GmbH now owns 215,449 shares of the medical equipment provider’s stock worth $3,652,000 after buying an additional 14,779 shares during the last quarter. Institutional investors and hedge funds own 50.22% of the company’s stock.

A number of analysts recently commented on the stock. ValuEngine downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Tuesday. Northland Securities boosted their target price on shares of BioLife Solutions from $18.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Maxim Group set a $26.00 target price on shares of BioLife Solutions and gave the stock a “buy” rating in a report on Tuesday, September 17th. BidaskClub downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Oppenheimer assumed coverage on shares of BioLife Solutions in a report on Wednesday, November 20th. They issued an “outperform” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $19.00.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Story: What is a Roth IRA?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.